Aliskiren as a novel therapeutic agent for hypertension and cardio-renal diseases

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 4, 2012, Pages 470-481

  Rashikh, Azhar ^a   Ahmad, Shibli Jameel ^a   Pillai, Krishna Kolappa ^a   Najmi, Abul Kalam ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

aliskiren; hypertension; plasma renin activity; renin angiotensin aldosterone system

Indexed keywords

ALISKIREN; ALLOPURINOL; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; CANDESARTAN; CELECOXIB; CILAZAPRIL; CIMETIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HANDLE REGION DECOY PEPTIDE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; MEVINOLIN; OMEGA 3 FATTY ACID; PEPTIDE; PLACEBO; RAMIPRIL; RENIN INHIBITOR; RIFAMPICIN; UNCLASSIFIED DRUG; VALSARTAN; VERAPAMIL; WARFARIN;

ALBUMINURIA; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; ATHEROSCLEROSIS; CARDIOTOXICITY; COMBINATION CHEMOTHERAPY; COUGHING; DIABETIC NEPHROPATHY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG UPTAKE; FATIGUE; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; GLUCOSE INTOLERANCE; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART PROTECTION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; IC 50; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY INJURY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTIPLE SCLEROSIS; NONHUMAN; PERITONEAL FIBROSIS; PROTEINURIA; RENAL PROTECTION; REVIEW; RHINOPHARYNGITIS; SINGLE DRUG DOSE; STEADY STATE; UNSPECIFIED SIDE EFFECT;

EID: 84859103996     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01414.x     Document Type: Review

References (107)

1. Rosamond W, et al,. Heart disease and stroke statistics 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115: e69-e171. (Pubitemid 46226160)
2. Baker KM, et al,. Cardiac actions of angiotensin II: role of an intracardiac renin-angiotensin system. Annu Rev Physiol 1992; 54: 227-241.
3. Jandeleit-Dahm K, Cooper ME,. Hypertension and diabetes: role of the renin-angiotensin system. Endocrinol Metab Clin North Am 2006; 35: 469-490. (Pubitemid 44321946)
4. Kim S, Iwao H,. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52: 11-34. (Pubitemid 30127593)
5. Dzau VJ,. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37: 1047-1052. (Pubitemid 32304002)
6. Buhler FR, et al,. Antihypertensive action of propranolol: specific anti-renin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension. Am J Cardiol 1973; 32: 511-522.
7. Pool JL, et al,. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007; 20: 11-20. (Pubitemid 46014059)
8. Campbell DJ,. Interpretation of plasma renin concentration in patients receiving aliskiren therapy. Hypertension 2008; 51: e27-e28.
9. Waldmeier F, et al,. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos 2007; 35: 1418-1428. (Pubitemid 47121784)
10. Wood JM, et al,. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003; 308: 698-705. (Pubitemid 36976519)
11. Stanton A,. Therapeutic potential of renin inhibitors in the management of cardiovascular disorders. Am J Cardiovasc Drugs 2003; 3: 389-394. (Pubitemid 38008675)
12. Staessen JA, et al,. Oral renin inhibitors. Lancet 2006; 368: 1449-1456. (Pubitemid 44573444)
13. Oparil S, et al,. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized double-blind trial. Lancet 2007; 370: 221-229. (Pubitemid 47069535)
14. Azizi M, et al,. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004; 15: 3126-3133. (Pubitemid 39578845)
15. Karlberg BE,. Cough and inhibition of the renin-angiotensin system. J Hypertens Suppl 1993; 11: S49-S52. (Pubitemid 23120562)
16. Gradman AH, et al,. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111: 1012-1018. (Pubitemid 40354519)
17. Fisher ND, Hollenberg NK,. Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol 2005; 16: 592-599. (Pubitemid 41725095)
18. Herron J, et al,. The novel renin inhibitor aliskiren is not associated with rebound effects on blood pressure or plasma renin activity following treatment withdrawal. J Clin Hypertens 2006; 8: A86.
19. Hollenberg NK, et al,. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998; 32: 387-392. (Pubitemid 28429123)
20. Veniant M, et al,. Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. J Clin Invest 1996; 98: 1966-1970. (Pubitemid 26376283)
21. Smithies O,. A mouse view of hypertension. Hypertension 1997; 30: 1318-1324. (Pubitemid 27528069)
22. Vaidyanathan S, et al,. Pharmacokinetics, safety, and tolerability of the oral renin inhibitor aliskiren in patients with hepatic impairment. J Clin Pharmacol 2007; 47: 192-200. (Pubitemid 46146485)
23. Nguyen G, et al,. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 10: 1417-1427. (Pubitemid 34596167)
24. Wood JM, et al,. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens 2005; 23: 417-426. (Pubitemid 40279646)
25. Cada DJ, et al,. Aliskiren. Hosp Pharm 2007; 42: 737-749.
26. Cheng JWM,. Aliskiren: renin inhibitor for hypertension management. Clin Ther 2008; 30: 31-47. (Pubitemid 351834725)
27. Azizi M, et al,. Renin inhibition with aliskiren: where are we now and where are we going? J Hypertens 2006; 24: 243-256. (Pubitemid 43348229)
28. Sica D, et al,. Aliskiren, an oral renin inhibitor, provides long-term antihypertensive efficacy and safety in patients with hypertension. Eur Heart J 2006; 27: P797.
29. Vaidyanathan S, et al,. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int J Clin Pract 2006; 60: 1343-1356. (Pubitemid 44560330)
30. Ferro A, et al,. Importance of renin in blood pressure regulation and therapeutic potential of renin inhibition. Int J Clin Pract 2006; 60: 577-581.
31. Meredith PA,. Role of trough to peak efficacy in the evaluation of antihypertensive therapy. J Hypertens Suppl 1998; 16: S59-S64.
32. Nussberger J, et al,. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension 2002; 39: E1-E8.
33. Shagdarsuren E, et al,. Complement activation in Angiotensin II-induced organ damage. Circ Res 2005; 97: 716-724. (Pubitemid 41416341)
34. Westermann D, et al,. Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure. Hypertension 2008; 52: 1068-1075.
35. Stegbauera J, et al,. Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proc Natl Acad Sci USA 2009; 106: 14942-14947.
36. Lu H, et al,. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest 2008; 118: 984-993. (Pubitemid 351364606)
37. Feldman DL, et al,. Effects of aliskiren on blood pressure, albuminuria, and (Pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008; 52: 130-136.
38. Singh VP, et al,. Intracellular angiotensin II production in diabetic rats. Is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes 2008; 57: 3297-3306.
39. Nussberger J, et al,. Renin inhibition by aliskiren prevents atherosclerosis progression comparison with irbesartan, atenolol and amlodipine. Hypertension 2008; 51: 1306-1311. (Pubitemid 351555942)
40. Gratze P, et al,. Energy metabolism in human renin-gene transgenic rats. Does renin contribute to obesity? Hypertension 2009; 53: 516-523.
41. Imanishi T, et al,. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension 2008; 52: 563-572.
42. Pilz B, et al,. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005; 46: 569-576. (Pubitemid 41376839)
43. Yamamoto E, et al,. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice. Hypertension 2009; 54: 633-638.
44. Dong YF, et al,. Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes. Curr Diab Rep 2009; 9: 447-452.
45. Dong YF, et al,. Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice. J Hypertens 2010; 28: 1554-1565.
46. Fischer R, et al,. Dietary n-3 polyunsaturated fatty acids and direct renin inhibition improve electrical remodeling in a model of high human renin hypertension. Hypertension 2008; 51: 540-546. (Pubitemid 351156445)
47. Feldt S, et al,. The putative (Pro)renin receptor blocker HRP fails to prevent (Pro)renin signaling. J Am Soc Nephrol 2008; 19: 743-748.
48. Dechend R, et al,. Low-dose renin inhibitor and low-dose AT1-receptor blocker therapy ameliorate target-organ damage in rats harbouring human renin and angiotensinogen genes. JRAAS. 2007; 8: 81-84. (Pubitemid 47272471)
49. Whaley-Connell A, et al,. Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat. Am J Physiol Renal Physiol 2010; 298: F655-F661.
50. Batenburg WW, et al,. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2008; 28: 1151-1157.
51. Habibi J, et al,. Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 Rat. Endocrinology 2008; 149: 5643-5653.
52. Vanourkova Z, et al,. Despite similar reduction of blood pressure and renal ANG II and ET-1 levels aliskiren but not losartan normalizes albuminuria in hypertensive Ren-2 rats. Physiol Res 2010; 59: 339-345.
53. Iwai M, et al,. Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabetic KK-A(y) mice. J Hypertens 2010; 28: 1471-1481.
54. Ke CY, et al,. Aliskiren ameliorates chlorhexidine digluconate-induced peritoneal fibrosis in rats. Eur J Clin Invest 2010; 40: 301-309.
55. Rakusan D, et al,. Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats. Am J Physiol Renal Physiol 2010; 299: F758-F766.
56. Wu WP, et al,. A reduction of unilateral ureteral obstruction-induced renal fibrosis by a therapy combining valsartan with aliskiren. Am J Physiol Renal Physiol 2010; 299: F929-F941.
57. Ino J, et al,. Dynamic observation of mechanically-injured mouse femoral artery reveals an antiinflammatory effect of renin inhibitor. Arterioscler Thromb Vasc Biol 2009; 29: 1858-1863.
58. Rashikh A, et al,. Protective effects of aliskiren in doxorubicin-induced acute cardiomyopathy in rats. Hum Exp Toxicol 2011; 30: 102-109.
59. Dieterle W, et al,. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Clin Pharmacol 2004; 58: 433-436. (Pubitemid 39312468)
60. Dieterle W, et al,. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther 2005; 43: 527-535. (Pubitemid 41684265)
61. Gradman AH, Kad R,. Renin inhibition in hypertension. J Am Coll Cardiol 2008; 51: 519-528.
62. Zhao C, et al,. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet 2006; 45: 1125-1134. (Pubitemid 44631391)
63. Verdecchia P, et al,. The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. Vasc Health Risk Manag 2008; 4: 971-981.
64. Uresin Y, et al,. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007; 8: 190-200.
65. Jordan J, et al,. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007; 49: 1047-1055. (Pubitemid 351664315)
66. Oh BH, et al,. Aliskiren, an oral rennin inhibitor, provides dose-dependent efficacy and sustained 24-h blood pressure control in patients with hypertension. J Am Coll Cardiol 2007; 49: 1157-1163.
67. Villamil A, et al,. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with HCTZ. J Hypertens 2007; 25: 217-226. (Pubitemid 44885684)
68. Azizi M, et al,. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. Clin J Am Soc Nephrol 2007; 2: 947-955.
69. Nickenig G, et al,. Efficacy of aliskiren/hydrochlorothiazide single-pill combinations in aliskiren nonresponders. Blood Press Suppl 2008; 2: 31-40.
70. Dietz R, et al,. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension. J Renin Angiotensin Aldosterone Syst 2008; 9: 163-175.
71. Andersen K, et al,. Comparative efficacy and safety of aliskiren, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008; 26: 589-599.
72. Parving HH, et al,. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-2446.
73. McMurray JJV, et al,. Effects of the oral direct renin inhibitor Aliskiren in patients with symptomatic heart failure for the Aliskiren Observation of Heart Failure Treatment (ALOFT) investigators. Circ Heart Fail 2008; 1: 17-24.
74. Solomon SD, et al,. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009; 119: 530-537.
75. Schmieder RE, et al,. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 2009; 119: 417-425.
76. Yarows SA, et al,. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study. Adv Ther 2008; 25: 1288-1302.
77. Duprez DA, et al,. The AGELESS Study: the effect of aliskiren vs ramipril alone or in combination with hydrochlorothiazide and amlodipine in patients >65 years of age with systolic hypertension. Circulation 2008; 118: S886-S887.
78. Persson F, et al,. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 2009; 32: 1873-1879.
79. Cherney DZI, et al,. Effect of direct renin inhibition on renal hemodynamic function, arterial stiffness, and endothelial function in humans with uncomplicated type 1 diabetes. Diabetes Care 2010; 33: 361-365.
80. Kushiro T, et al,. Aliskiren, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res 2006; 29: 997-1005. (Pubitemid 46206586)
81. O'Brien E, et al,. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin- converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2007; 49: 276-284. (Pubitemid 46143002)
82. Nussberger J, et al,. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. Int J Clin Pract 2007; 61: 1461-1468. (Pubitemid 47228610)
83. Ayalasomayajula S, et al,. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects. Curr Med Res Opin 2008; 24: 717-726. (Pubitemid 351428984)
84. Vaidyanathan S, et al,. Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5- mononitrate in healthy subjects. Cardiovasc Ther 2008; 26: 238-246.
85. Vaidyanathan S, et al,. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol 2008; 48: 1323-1338.
86. Persson F, et al,. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 2008; 73: 1419-1425. (Pubitemid 351770494)
87. Limoges D, et al,. A study of dose-proportionality in the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects. Int J Clin Pharmacol Ther 2008; 46: 252-258. (Pubitemid 351663162)
88. Freel EM, et al,. Aldosterone status associated with insulin resistance in patients with heart failure-data from the ALOFT study. Heart 2009; 95: 1920-1924.
89. Palatini P, et al,. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. J Hum Hypertens 2010; 24: 93-103.
90. Scirica BM, et al,. Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial. Eur Heart J 2010; 31: 1993-2005.
91. Tapaninen T, et al,. Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren. Eur J Clin Pharmacol 2010; 66: 497-502.
92. Lõpez V, et al,. Renin-angiotensin system dual blockade using angiotensin receptor plus aliskiren decreases severe proteinuria in kidney transplant recipients. Transplant Proc 2010; 42: 2883-2885.
93. Persson F, et al,. Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial. Diabetologia 2010; 53: 1576-1580.
94. Fogari R, et al,. Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome. Horm Metab Res 2010; 42: 892-896.
95. Gheorghiade M, et al,. Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). Eur J Heart Fail 2011; 13: 100-106.
96. Rebello S, et al,. Effect of verapamil on the pharmacokinetics of aliskiren in healthy participants. Clin Pharmacol 2011; 51: 218-228.
97. Phillips LM, et al,. The renin inhibitor aliskiren attenuates high-glucose induced extracellular matrix synthesis and prevents apoptosis in cultured podocytes. Nephron Exp Nephrol 2011; 118: e49-e59.
98. Schweizer J, et al,. Efficacy and tolerability of aliskiren 300 mg/hydrochlorothiazide 25 mg (± amlodipine 5 mg) in hypertensive patients not controlled by candesartan 32 mg plus HCT 25 mg. Curr Med Res Opin 2011; 27: 131-140.
99. Rahuel J, et al,. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol 2000; 7: 493-504. (Pubitemid 30466984)
100. Sanoski CA,. Aliskiren: an oral direct renin inhibitor for the treatment of hypertension. Pharmacotherapy 2009; 29: 193-212.
101. Buczko W, Hermanowicz JM,. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor. Pharmacol Rep 2008; 60: 623-631.
102. Tassell BWV, Munger MA,. Aliskiren for renin inhibition: a new class of antihypertensives. Ann Pharmacother 2007; 41: 456-464. (Pubitemid 46536037)
103. Weir MR, et al,. Antihypertensive efficacy, safety and tolerability of the oral renin inhibitor aliskiren in patients with hypertension: A pooled analysis. J Am Soc Hypertens 2007; 1: 264-277. (Pubitemid 47091546)
104. Malmqvist K, et al,. Relationships between left ventricular mass and the renin-angiotensin system, catecholamines, insulin and leptin. J Intern Med 2002; 252: 430-439. (Pubitemid 36706574)
105. Maggioni AP,. Efficacy of angiotensin receptor blockers in cardiovascular disease. Cardiovasc Drugs Ther 2006; 20: 295-308. (Pubitemid 44710747)
106. Greenberg B, et al,. Role of aldosterone blockade for treatment of heart failure and post-acute myocardial infarction. Am J Cardiol 2006; 97: 34F-40F.
107. Parving HH, et al,. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009; 24: 1663-1671.